Mode
Text Size
Log in / Sign up
N/A N=22 Diagnostic

Diagnosing Intensive Care Unit (ICU) Acquired Weakness

ICU Acquired Weakness

Enrolled (actual)
22
Serious AEs
0.0%
Results posted
Aug 2022
Primary outcome: Primary: Peak Acceleration Measured in Extensor Carpi Radialis Longus — 0.476; 1.639; 0.541; 1.608 units of Gravity

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Clinical Electrical Stimulator (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Emory University
Primary completion
Jun 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Peak Acceleration Measured in Extensor Carpi Radialis Longus
0.476; 1.639; 0.541; 1.608; 0.373; 1.300
PRIMARY
Peak Acceleration Measured in Tibialis Anterior
0.105; 1.115; 0.102; 1.029; 0.101; 0.593
PRIMARY
Time to Peak Acceleration Measured in Extensor Carpi Radialis Longus
64.7; 119.5; 9.8; 64.6; 1.5; 33.7
PRIMARY
Time to Peak Acceleration Measured in Tibialis Anterior
45.5; 100.1; 22.0; 32.3; 8.8; 19.3
PRIMARY
End Acceleration Measured in Extensor Carpi Radialis Longus
0.289; 1.383; 0.147; 1.021; 0.239; 1.133
PRIMARY
End Acceleration Measured in Tibialis Anterior
0.057; 1.088; 0.042; 0.767; 0.059; 0.640
PRIMARY
Fatigue Ratio Measured in Extensor Carpi Radialis Longus
0.578; 0.862; 0.306; 0.562; 0.639; 0.707
PRIMARY
Fatigue Ratio Measured in Tibialis Anterior
0.610; 0.899; 0.471; 0.572; 0.437; 0.549

Summary

The goal of this study is to develop a non-invasive test to diagnose intensive care unit (ICU) acquired weakness that can be administered to both responsive and non-responsive patients. Study participation will involve the measurement of muscle fatigue during a single 30 minute session. Skeletal muscle will be stimulated with an FDA approved clinical electrical stimulator and accelerations will be passively recorded with an accelerometer.

Eligibility Criteria

Inclusion Criteria

  • Patients transferred from the ICU to a lower level of care within the past 7 days
  • Mechanical ventilation for greater than 7 days while in the ICU
  • Ability to understand English and provide written consent

Exclusion Criteria

  • Vulnerable populations including: patients who are pregnant or prisoners
  • Patients who are unable to understand English or provide written consent
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04166630). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search